Literature DB >> 32497371

Multivalent Antibody-Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune Killing.

Annemiek Uvyn1, Bruno G De Geest1.   

Abstract

Antibody-recruiting molecules (ARMs) are a novel class of immunotherapeutics. They are capable of introducing antibodies onto disease-relevant targets such as cancer cells, bacterial cells or viruses. This can induce antibody-mediated immune responses such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and antibody-dependent phagocytosis (ADCP), which can kill the pathogen. In contrast to the classic ARMs, multivalent ARMs could offer the advantage of increasing the efficiency of antibody recruitment and subsequent innate immune killing. Such compounds consist of multiple target-binding termini (TBT) and/or antibody-binding termini (ABT). Those multivalent interactions are able to convert low binding affinities into increased binding avidities. This minireview summarizes the current status of multivalent ARMs and gives insight into possible benefits, hurdles still to be overcome and future perspectives.
© 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  antibodies; cancer; glycans; innate immunity; polymers

Mesh:

Substances:

Year:  2020        PMID: 32497371      PMCID: PMC7116353          DOI: 10.1002/cbic.202000261

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  60 in total

Review 1.  Complement. First of two parts.

Authors:  M J Walport
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

2.  Cell surface clicking of antibody-recruiting polymers to metabolically azide-labeled cancer cells.

Authors:  Annemiek Uvyn; Ruben De Coen; Olivier De Wever; Kim Deswarte; Bart N Lambrecht; Bruno G De Geest
Journal:  Chem Commun (Camb)       Date:  2019-09-10       Impact factor: 6.222

3.  Exploring binding and effector functions of natural human antibodies using synthetic immunomodulators.

Authors:  Charles E Jakobsche; Christopher G Parker; Ran N Tao; Mariya D Kolesnikova; Eugene F Douglass; David A Spiegel
Journal:  ACS Chem Biol       Date:  2013-09-20       Impact factor: 5.100

Review 4.  Complement in cancer: untangling an intricate relationship.

Authors:  Edimara S Reis; Dimitrios C Mastellos; Daniel Ricklin; Alberto Mantovani; John D Lambris
Journal:  Nat Rev Immunol       Date:  2017-09-18       Impact factor: 53.106

5.  Synthetic Rhamnose Glycopolymer Cell-Surface Receptor for Endogenous Antibody Recruitment.

Authors:  Ruben De Coen; Lutz Nuhn; Chamani Perera; Maria Arista-Romero; Martijn D P Risseeuw; Alec Freyn; Raffael Nachbagauer; Lorenzo Albertazzi; Serge Van Calenbergh; David A Spiegel; Blake R Peterson; Bruno G De Geest
Journal:  Biomacromolecules       Date:  2020-01-08       Impact factor: 6.988

Review 6.  Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

Authors:  Patrick J McEnaney; Christopher G Parker; Andrew X Zhang; David A Spiegel
Journal:  ACS Chem Biol       Date:  2012-07-03       Impact factor: 5.100

Review 7.  Antibody-Dependent Phagocytosis of Tumor Cells by Macrophages: A Potent Effector Mechanism of Monoclonal Antibody Therapy of Cancer.

Authors:  Nuray Gül; Marjolein van Egmond
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

8.  Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide.

Authors:  Vijay M Krishnamurthy; Lee J Quinton; Lara A Estroff; Steven J Metallo; Jessica M Isaacs; Joseph P Mizgerd; George M Whitesides
Journal:  Biomaterials       Date:  2006-03-09       Impact factor: 12.479

9.  Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier.

Authors:  T Saga; R D Neumann; T Heya; J Sato; S Kinuya; N Le; C H Paik; J N Weinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

10.  Multifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer Cells.

Authors:  Benjamin Liet; Eugénie Laigre; David Goyard; Biagio Todaro; Claire Tiertant; Didier Boturyn; Nathalie Berthet; Olivier Renaudet
Journal:  Chemistry       Date:  2019-10-15       Impact factor: 5.236

View more
  4 in total

1.  Metabolic labelling of cancer cells with glycodendrimers stimulate immune-mediated cytotoxicity.

Authors:  David Goyard; Peremobowei Iyanu Diriwari; Nathalie Berthet
Journal:  RSC Med Chem       Date:  2021-11-09

Review 2.  Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer.

Authors:  Bing-Tao Zhai; Huan Tian; Jing Sun; Jun-Bo Zou; Xiao-Fei Zhang; Jiang-Xue Cheng; Ya-Jun Shi; Yu Fan; Dong-Yan Guo
Journal:  J Transl Med       Date:  2022-03-18       Impact factor: 5.531

3.  Poly-L-Lysine-Based αGal-Glycoconjugates for Treating Anti-αGal IgE-Mediated Diseases.

Authors:  Sara Olivera-Ardid; Daniel Bello-Gil; Alexander Tuzikov; Ricardo N Araujo; Yara Ferrero-Alves; Blanca Esther García Figueroa; Moisés Labrador-Horrillo; Ana L García-Pérez; Nicolai Bovin; Rafael Mañez
Journal:  Front Immunol       Date:  2022-03-31       Impact factor: 7.561

4.  Optimization of Multivalent Gold Nanoparticle Vaccines Eliciting Humoral and Cellular Immunity in an In Vivo Model of Enterohemorrhagic Escherichia coli O157:H7 Colonization.

Authors:  Javier I Sanchez-Villamil; Daniel Tapia; Alfredo G Torres
Journal:  mSphere       Date:  2022-01-19       Impact factor: 4.389

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.